Submit this documentation within 14 days of sending your refund request
doi: 10.1002/hep.29238 201 FangYJiLZhuCXiaoYZhangJLuJet al
What stands out: Enforcement focus on mass-marketing, not patient-specific compounding Clear limits on advertising claims, including prohibitions on calling compounded products generic, the same as, or clinically proven Reinforcement of FD&C Act authorities, including misbranding provisions and Section 503A requirements Shift as shortages resolve, removing the legal basis for broad compounding of GLP-1 drugs Expanded compliance tools, including warning letters, seizure, and injunction where violations persist Bottom line: This signals a firmer FDA posture as the GLP-1 market matures, reinforcing long-standing distinctions between FDA-approved drugs and unapproved compounded preparations, particularly when promoted directly to consumers at scale
Winter travel (December through February) Winter introduces the opposite problem: freezing
That one structural differencelinear vs
Two more will be voted on later today